Barclays PLC Has $34,000 Stock Position in Renovaro Inc. (NASDAQ:RENB)

Barclays PLC lifted its stake in shares of Renovaro Inc. (NASDAQ:RENB) by 315.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 69,531 shares of the company’s stock after purchasing an additional 52,804 shares during the period. Barclays PLC’s holdings in Renovaro were worth $34,000 at the end of the most recent quarter.

Separately, Rhumbline Advisers acquired a new position in Renovaro during the second quarter worth $79,000. Institutional investors and hedge funds own 71.41% of the company’s stock.

Renovaro Price Performance

Shares of RENB stock opened at $0.89 on Friday. The company has a fifty day moving average price of $1.01 and a two-hundred day moving average price of $0.82. Renovaro Inc. has a one year low of $0.40 and a one year high of $5.25. The stock has a market cap of $141.36 million, a P/E ratio of -0.93 and a beta of 0.66.

About Renovaro

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.